KPI-121 1% Ophthalmic Suspension dosed BID

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Post Surgical Ocular Inflammation and Pain

Drug Information

Target Indication

Post Surgical Ocular Inflammation and Pain

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

KALA

Kala Pharmaceuticals, Inc.

Related Pipeline

Kerato Conjunctivitis Sicca

Dry Eye Syndromes

Ocular Infections, Irritations and Inflammations

Dry Eye Syndromes

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts